192726-06-0

Basic information

• Product Name: N-(4-Amino-1-benzyl-3-hydroxy-5-phenyl-pentyl)-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide 5-oxopyrrolidine-2-carboxylic acid
• Synonyms: (S)-N-((2S,4S,5S)-5-AMino-4-hydroxy-1,6-diphenylhexan-2-yl)-3-Methyl-2-(2-oxotetrahydropyriMidin-1(2H)-yl)butanaMide coMpd with (S)-5-oxopyrrolidine-2-carboxylic acid;n-(4-amino-1-benzyl-3-hydroxy-5-phenyl-pentyl)-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide 5-oxopyrrolidine-2-carboxylic acid;N-(4-Amino-1-Benzyl-3-Hydroxy-5-Phenyl-Pentyl)-3-Methyl-2-(2-Oxo-Tetrahydro-Pyrimidin-1-Yl)-Butyramide,Compound With 5-Oxopyrrolidine-2-Carboxylic Acid;N-(4-Amino-1-benzyl-3-hydroxy-5-phenyl-pentyl)-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide 5-oxopyrrolidine-2-carboxylic acid
• CAS NO: 192726-06-0
• Molecular Formula: C27H38N4O3.C5H7NO3
• Molecular Weight: 595.74
• Mol File: 192726-06-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(4-Amino-1-benzyl-3-hydroxy-5-phenyl-pentyl)-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide 5-oxopyrrolidine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-Amino-1-benzyl-3-hydroxy-5-phenyl-pentyl)-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide 5-oxopyrrolidine-2-carboxylic acid(192726-06-0)
• EPA Substance Registry System: N-(4-Amino-1-benzyl-3-hydroxy-5-phenyl-pentyl)-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide 5-oxopyrrolidine-2-carboxylic acid(192726-06-0)

Safety Data

• Hazardous Substances Data: 192726-06-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(4-Amino-1-benzyl-3-hydroxy-5-phenyl-pentyl)-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide 5-oxopyrrolidine-2-carboxylic acid is used as a potential pharmaceutical compound for its diverse functional groups that may contribute to its therapeutic properties.
Used in Chemical Research:
This complex molecule is used as a subject of study in chemical research, where its structure and properties can be analyzed using techniques such as NMR, IR, and mass spectroscopy to understand its potential applications and interactions.
Used in Drug Development:
Due to its complex structure and the presence of various functional groups, N-(4-Amino-1-benzyl-3-hydroxy-5-phenyl-pentyl)-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide 5-oxopyrrolidine-2-carboxylic acid may be used in drug development for the creation of new therapeutic agents, particularly in the fields of medicine and biochemistry.

Upstream product

• 192726-05-9 (2S,3S,5S)-2-amino-3-hydroxy-5-(2S-(2-oxotetrahydropyrimidin-2-yl)-3-methylbutanoyl)amino-1,6-diphenylhexane 
• 98-79-3 L-Pyroglutamic acid 
• 192726-04-8 (2S,3S,5S)-2-N,N-dibenzylamino-3-hydroxy-5-(2S-(2-oxotetrahydropyrimidin-2-yl)-3-methylbutanoyl)amino-1,6-diphenylhexane 
• 192725-50-1 (S)-tetrahydro-α-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetic acid 
• 72-18-4 L-valine 
• 126147-70-4 (2S)-3-Methyl-2-(phenoxycarbonyl)aminobutyric acid 
• 192800-77-4 2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl chloride 
• 156732-13-7 (5S)-2-amino-5-dibenzylamino-4-oxo-1,6-diphenylhex-2-ene 

Relevant articles and documents

AN IMPROVED PROCESS FOR PREPARATION OF LOPINAVIR AND ITS INTERMEDIATES THEREOF

The present invention generally relates to an improved process for preparation of lopinavir and its intermediates through formation of tartrate salt of compound of Formula (III).

PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE (2S,3S,5S)-5-AMINO-2-N,N-DIBENZYLAMINO-3-HYDROXY-1,6-DIPHENYLHEXANE

The present invention relates to the purification of (2S,3S,5S)-5-amino-2-N,N-dibenzylamino-3-hydroxy-1,6-diphenylhexane (III) by making its crystalline acid addition salt, which can be used as such to produce Lopinavir/Ritonavir with high purity and yield. Formula III

AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE (2S,3S,5S)-5-AMINO-2-N,N-DIBENZYLAMINO-3-HYDROXY-1,6-DIPHENYLHEXANE

The present invention relates to the purification of (2S,3S,5S)-5-amino-2-N,N-dibenzylamino-3-hydroxy-1,6-diphenylhexane (III) by making its crystalline acid addition salt, which can be used as such to produce Lopinavir /Ritonavir with high purity and yield. Formula III

Processes and intermediates for preparing retroviral protease inhibitors

The instant invention provides processes and intermediates employed in the synthesis of ((2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyrimid-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane and analogs thereof.

Retroviral protease inhibiting compounds

A compound comprising a substituent of the formula (II) is disclosed as an HIV protease inhibitor. Intermediates for making such compounds and processes for making such intermediates are also disclosed.

Synthesis of HIV protease inhibitor ABT-378 (lopinavir)

A large scale process for the synthesis of HIV protease inhibitor candidate ABT-378 has been developed which utilizes an intermediate common to the synthesis of ritonavir, Abbott's first generation compound. The synthesis relies on the sequential acylation of this intermediate which is carried through as a mixture of diastereomers until the penultimate step. A synthesis of acid 5, derived from L-valine, is also reported.